Depression Research Study
Researchers at Dell Medical School at the University of Texas at Austin are testing a treatment for depression symptoms in patients for whom some antidepressants do not work.
Fast Facts
Diagnosed with Depression and in Current Depressive Episode
Ages 18+
No history of psychotic disorders or borderline personality disorder
May Be Compensated
Conducted in Austin, TX
Study Background
Researchers at UT Austin’s Dell Medical School are testing a therapy to see if it can help address symptoms of Treatment-Resistant Depression.
This study will examine individuals diagnosed with depression. We will administer one of the three study treatments to participants to determine their effectiveness in addressing symptoms of depression in individuals for whom some antidepressants do not work.
Study Background
Researchers at UT Austin’s Dell Medical School are testing three therapies to see if they can help address symptoms of Treatment Resistant Depression.
These studies will examine individuals diagnosed with depression who have had an inadequate response to at least 1 antidepressant therapy in their current depressive episode. We will administer one of the three study treatments to participants to determine their effectiveness in addressing symptoms of depression in individuals for whom some antidepressants do not work.
Additional Information
Through this study, we aim to test the efficacy of three treatments for symptoms of depression in patients for whom some antidepressants do not work. We hope that this research can help us identify better therapies for Treatment Resistant Depression.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Diagnosed with depression and in current depressive episode
- No history of psychotic disorders or borderline personality disorder
- No current primary diagnosis of PTSD, OCD, or eating disorders
- No substance use disorder
- Willing/able to provide medical records to verify diagnostic and treatment history
The COMP006 study will last between 55 and 62 weeks. Participants will attend between 15 and 25 in-person visits and 2 and 6 remote visits. They will receive 2x randomized treatment in Part A (the first 9 weeks after screening), 1x randomized treatment if clinically applicable in Part B (the next 17 weeks), and 1x open-label retreatment if clinically applicable in Part C (the final 26 weeks).
Participants may be compensated for their involvement in the study.
There is no cost for you to participate in our research study.